AbbVie Inc news

   Watch this stock
Showing stories 1 - 10 of about 163   

Articles published

ABBV 118.60 +3.70 (3.22%)
price chart
Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America?
In the past, AbbVie's said that peak sales of Imbruvica, a cancer drug, could be $7 billion. With a recent label expansion for use in graft-versus-host disease and full-year global sales of $2.573 billion in 2017, up 40.5% from 2016, it appears to be ...
AbbVie: Time To Trim Our Position?
AbbVie has been the single best performer in the March to Freedom Fund. The position has returned almost 270% since inception.
Buy or Sell? What Analysts Recommends: US Bancorp (USB), AbbVie Inc. (ABBV)  StockNewsJournal
These 3 Drugs Are Critical to AbbVie's Success  Motley Fool
AbbVie's New Capital Return Program And How It Impacts Expected Total Returns
During its relatively short life as a publicly traded company, AbbVie Inc. (ABBV) has made quite a name for itself among dividend growth investors.
Why AbbVie Inc.'s Shares Rocketed 16% in January
Humira's $18.4 billion in sales accounted for about 65% of AbbVie's total revenue last year, and some of its patents have already started to expire.
AbbVie: Looking Very Attractive In 2018  Seeking Alpha
Don't Miss Out, Act Now On AbbVie
While the whole pharma sector has been truly out of favor with investors during 2017, AbbVie's has been very much in favor.
AbbVie's Bright Future
If you're long AbbVie Inc (ABBV) you've been pretty happy lately. Shares jumped a whole 13% on the company's fourth quarter earnings results.
AbbVie Inc Stock Soars on Strong Q4 Earnings Beat  Yahoo Finance
3 Things Driving AbbVie Inc. Stock After Q4 Earnings Report
AbbVie to buy back $10 billion of shares, raises dividend
(Reuters) - AbbVie Inc (ABBV.N) said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped the benefits of U.S.
AbbVie stock rises after dividend boosted 35%, new $10 billion buyback program  MarketWatch
Is Now a Good Time to Buy AbbVie?
If you look at Mavyret, I think that's probably the stiffest challenge yet that Gilead Sciences has faced in the hepatitis C. It should still be able to provide billions of dollars in revenue for AbbVie over the course of the next few years. And then ...
AbbVie Looks Positioned For Outperformance
Past performance is no guarantee of future returns, and system implementation in real life can be more difficult than it seems to be, so backtested performance needs to be interpreted with caution.
AbbVie Inc (ABBV) Files 10-K for the Fiscal Year Ended on December 31, 2017
AbbVie Inc (NYSE:ABBV) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic ...